학술논문
COVID‐19 disease in patients with chronic neutropenia: The experience from the European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias.
Document Type
Article
Author
Spanoudakis, Michail; Yilmaz Karapinar, Deniz; Dale, David; Bolyard, Audrey Anna; Tran, Emily; Roganovic, Jelena; Bartels, Marije; Kapor, Suncica; Guardo, Daniela; Yacobovich, Joanne; Nilsson, Christer; Bezzerri, Valentino; Cipolli, Marco; Pegoraro, Anna; Aleksov, Emil; Guenova, Margarita; Dufour, Carlo; Fioredda, Francesca; Papadaki, Helen A.; Palmblad, Jan
Source
Subject
*COVID-19
*DIAGNOSIS
*NEUTROPENIA
*COVID-19 pandemic
*CHRONIC diseases
*TETRALOGY of Fallot
*
*
*
*
*
Language
ISSN
0007-1048
Abstract
A study conducted by the European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias (EuNet-INNOCHRON) and other organizations examined the impact of COVID-19 on patients with chronic neutropenia (CNP). The study collected data from 57 CNP patients infected with SARS-CoV-2 between March 2020 and May 2022. The findings showed that CNP patients experienced similar symptoms to the general population, with fever, cough, and musculoskeletal pains being the most frequently reported. The study also found that isolated CNP did not increase the risk of severe COVID-19 infection unless other comorbidities were present. Patients on long-term granulocyte colony-stimulating factor (G-CSF) treatment were more likely to develop musculoskeletal symptoms and shortness of breath, but these symptoms were not severe enough to require hospitalization. The study concluded that CNP patients should be treated according to local protocols and that initiation of G-CSF treatment is generally not necessary. Further research is needed to assess the relative susceptibility of CNP patients to SARS-CoV-2. [Extracted from the article]